SSR 241586

for the treatment of schizophrenia and irritable bowel syndrome; structure in first source

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

1.	Cochi, Anne: 2 articles (04/2011 - 08/2010)
2.	Cossy, Janine: 2 articles (04/2011 - 08/2010)
3.	Métro, Thomas-Xavier: 2 articles (04/2011 - 08/2010)
4.	Gomez Pardo, Domingo: 1 article (04/2011)
5.	Pardo, Domingo Gomez: 1 article (08/2010)

1.	Irritable Bowel Syndrome (Syndrome, Irritable Bowel) 04/15/2011 - "SSR 241586 is a 2,2-disubstituted morpholine, developed by Sanofi-Aventis, which is active in the treatment of schizophrenia and irritable bowel syndrome (IBS). " 08/20/2010 - "An organo-catalyzed Henry reaction, applied to an alpha-keto ester, has allowed the enantioselective synthesis of SSR 241586, a 2,2-disubstituted morpholine active in the treatment of schizophrenia and irritable bowel syndrome (IBS)."
2.	Schizophrenia (Dementia Praecox) 04/15/2011 - "SSR 241586 is a 2,2-disubstituted morpholine, developed by Sanofi-Aventis, which is active in the treatment of schizophrenia and irritable bowel syndrome (IBS). " 08/20/2010 - "An organo-catalyzed Henry reaction, applied to an alpha-keto ester, has allowed the enantioselective synthesis of SSR 241586, a 2,2-disubstituted morpholine active in the treatment of schizophrenia and irritable bowel syndrome (IBS)."